PATENT CLAIM ANALYSIS

Application Number: 15880160
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "257000"]

Abstract:
The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.

Claim (Index 56):
The dosing regimen of  claim 48  wherein the sustained release depot formulation is an aqueous nanoparticle suspension consists essentially of\n (a) 156 mg/ml of the paliperidone palmitate having an average particle size (d50) of from about 1600 nm to about 900 nm; \n (b) 12 mg/ml of polysorbate 20; \n (c) one or more buffering agents sufficient to render the composition neutral to very slightly basic (pH 8.5); \n (d) 30 mg/ml of a suspending agent wherein the suspending agent is polyethylene glycol 4000; and \n (e) water q.s. ad 100%.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 86.0
- Lexical Diversity: 1.05
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12337144', '15090889', '14555273', '14555287', '13500623']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7489180524528487
- 35 USC 102 Novelty (BERT): 0.6984223708345875
- Combined Prediction Score: 0.7438684842910226
- Mean Citation Score: 425.511776
- Max Citation Score: 771.9951
- Similarity Product: 684.6982431248188

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test